Expertise in
19
conditions

Dr. Dennis R. Scribner

Obstetrics and Gynecology
2222 E Highland Ave Ste 130, 
Phoenix, AZ 
Accepting New Patients
Offers Telehealth
Expertise in
19
conditions
2222 E Highland Ave Ste 130, 
Phoenix, AZ 

Overview

Dennis Scribner is an Obstetrics and Gynecologist practicing medicine in Phoenix, Arizona.

Dr. Scribner is highly rated in 19 conditions, according to our data. His clinical expertise encompasses Endometrial Cancer, Endometrial Stromal Sarcoma, Malignant Mixed Mullerian Tumor, Vaginectomy, and Bladder Reconstruction.

Dr. Scribner is board certified in American Board Of Obstetrics & Gynecology. He is actively involved in clinical research, co-authoring 3 peer reviewed articles and participating in 5 clinical trials. Dr. Scribner is currently accepting new patients.

Specialties

Obstetrics and Gynecology

Licenses

Obstetrics & Gynecology in AZ

Board Certifications

American Board Of Obstetrics & Gynecology

Fellowships

University of Oklahoma Health Science Center

Hospital Affiliations

Yavapai Regional Medical Center
Honorhealth Scottsdale Shea Medical Center
Abrazo Arrowhead Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
MercyCare
  • EPO
  • HMO
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

Arizona Oncology Associates
2222 E Highland Ave Ste 130, Phoenix, AZ 85016

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women With Recurrent or Persistent Endometrial Cancer
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women With Recurrent or Persistent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Procedure, Biological
Study Phase: Phase 2
A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Cediranib Maleate, Durvalumab, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan Hydrochloride
Study Phase: Phase 2
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Other, Drug, Procedure, Biological
Study Drugs: Carboplatin, Paclitaxel, Pembrolizumab
Study Phase: Phase 3
A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma
A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: June 15, 2026
Intervention Type: Procedure, Drug
Study Drug: Tazemetostat
Study Phase: Phase 2
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Enrollment Status: Active_not_recruiting
Publish Date: March 24, 2026
Intervention Type: Drug, Procedure
Study Drugs: Carboplatin, Letrozole, Paclitaxel
Study Phase: Phase 3
View 4 Less Clinical Trials

3 Total Publications

Single-site laparoscopic management of a large adnexal mass.
Single-site laparoscopic management of a large adnexal mass.
Journal: JSLS : Journal of the Society of Laparoendoscopic Surgeons
Published: August 09, 2013
Similar Doctors
Expertise in
5
conditions
Dr. Mario E. Castellanos
Obstetrics and Gynecology
Expertise in
5
conditions
Dr. Mario E. Castellanos
Obstetrics and Gynecology
Referral may be required

Dignity Health Medical Group Pelvic Pain And Surgery-St. Joseph's

500 W Thomas Rd Ste 680, 
Phoenix, AZ 
 (3.0 miles away)
602-406-6017
Languages Spoken:
English
See accepted insurances

Mario Castellanos is an Obstetrics and Gynecologist practicing medicine in Phoenix, Arizona. Dr. Castellanos is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Pudendal Neuralgia, Giant Axonal Neuropathy, Wallerian Degeneration, Nerve Decompression, and Intrauterine Device Insertion.

Expertise in
21
conditions
Dr. Ali Azadi
Obstetrics and Gynecology
Expertise in
21
conditions
Dr. Ali Azadi
Obstetrics and Gynecology
Referral may be required
Before you request

Star Clinic/Star Urogynecology

14155 N 83rd Ave, Bldg 6, Ste 138, 
Peoria, AZ 
 (13.8 miles away)
623-271-8666
Languages Spoken:
English, Farsi
See accepted insurances
Accepting New Patients
Offers Telehealth

Ali Azadi is an Obstetrics and Gynecologist practicing medicine in Peoria, Arizona. Dr. Azadi is highly rated in 21 conditions, according to our data. His clinical expertise encompasses Stress Urinary Incontinence, Uterine Prolapse, Urinary Incontinence, Hysterectomy, and Endoscopy. Dr. Azadi is board certified in OB & Gyn (Sub: Female Pelvic Med/Reconstruct Surg), American Board Of Obstetrics & Gynecology, and Obstetrics & Gynecology. Dr. Azadi is currently accepting new patients.

Expertise in
22
conditions
Dr. Deborah D. Wilson
Obstetrics and Gynecology
Expertise in
22
conditions
Dr. Deborah D. Wilson
Obstetrics and Gynecology
Referral may be required

Deborah Wilson

10250 N 92nd St Ste 102, 
Scottsdale, AZ 
 (8.9 miles away)
480-860-4791
Languages Spoken:
English, French, Italian, Polish, Russian
See accepted insurances
Accepting New Patients
Offers Telehealth

Deborah Wilson is an Obstetrics and Gynecologist practicing medicine in Scottsdale, Arizona. Dr. Wilson is highly rated in 22 conditions, according to our data. Her clinical expertise encompasses Menopause, Angiomyoma, Uterine Fibroids, Pelvic Inflammatory Disease, and Intrauterine Device Insertion. Dr. Wilson is board certified in American Board Of Obstetrics & Gynecology. Dr. Wilson is currently accepting new patients.

Frequently Asked Questions about Dr. Dennis R. Scribner

How do I make an appointment with Dr. Dennis R. Scribner?

You can book an appointment with Dr. Dennis R. Scribner by calling their office at 602-277-4868. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Dennis R. Scribner a top-rated expert for Endometrial Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Dennis R. Scribner is classified as an Distinguished expert for Endometrial Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Dennis R. Scribner specialize in?

While Dr. Dennis R. Scribner is a Obstetrics and Gynecology, they have specific expertise in Endometrial Cancer, Endometrial Stromal Sarcoma, and Malignant Mixed Mullerian Tumor. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Obstetrics and Gynecology.

Does Dr. Dennis R. Scribner participate in research or clinical trials?

Yes. Dr. Dennis R. Scribner has published 3 articles and abstracts on conditions like Endometrial Cancer. You can view a list of Dr. Dennis R. Scribner's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Dennis R. Scribner accept my insurance?

Dr. Dennis R. Scribner accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 602-277-4868 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Scribner's expertise for a condition
ConditionClose
    View All 13 Advanced Conditions
    View All 11 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile